|1.||Tian, Zhigang: 18 articles (12/2014 - 11/2005)|
|2.||Sun, Rui: 14 articles (05/2014 - 11/2004)|
|3.||Wei, Haiming: 13 articles (05/2014 - 11/2005)|
|4.||Salazar, Andres M: 9 articles (12/2015 - 01/2009)|
|5.||Imaizumi, Tadaatsu: 8 articles (05/2015 - 08/2004)|
|6.||Meyer, Urs: 8 articles (02/2015 - 07/2006)|
|7.||Akira, Shizuo: 8 articles (10/2014 - 01/2004)|
|8.||Gao, Bin: 8 articles (04/2011 - 11/2004)|
|9.||Seya, Tsukasa: 7 articles (08/2015 - 12/2006)|
|10.||Matsumoto, Misako: 7 articles (08/2015 - 12/2006)|
12/01/2005 - "In contrast, polyriboinosinic : polyribocytidylic acid [poly(I : C); 10 or 100 microg per mouse at 12 h before infection], a potent IFN inducer, improved the survival rate and decreased the tissue viral titres after EV71 challenge, which correlated with an increase in serum IFN-alpha concentration, the percentage of dendritic cells, their expression of major histocompatibility complex class II molecule and IFN-alpha in spleen. "
03/01/2005 - "In addition, we demonstrated that administration of poly(I:C) with either A/Beijing (H1N1) or A/Yamagata (H1N1) vaccine conferred complete protection against PR8 challenge in this mouse nasal infection model, suggesting that poly(I:C) possessed cross-protection ability against variant viruses. "
01/01/2011 - "Our study presented the first evidence to show that activation of TLR3 is effective in blocking DENV2 replication via IFN-β, providing an experimental clue that poly(I:C) may be a promising immunomodulatory agent against DENV infection and might be applicable for clinical prevention."
10/01/1985 - "Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice."
08/01/2013 - "In an additional experiment, we demonstrated that the protective role of poly I:C is reproducible and elicits a specific antiviral response as immune-priming with heat-killed Vibrio splendidus provided no protection against subsequent viral infection. "
06/01/2013 - "Human patients with cervical cancer exhibited a marked decrease in the frequency of DCs; however, ex vivo treatment with E7(44-62) and poly(I:C) restored DC frequency. "
03/01/2014 - "Herein, we report that the combinatorial therapy of polyinosinic-polycytidylic acid (poly-IC) and antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody (mAb) can be implemented with good results for tumors where no known TAAs have been identified. "
01/01/2009 - "Of the TLR agonists, CpG and poly(I:C) also slowed tumor growth, and the combination of these two TLR agonists was more effective than either agent alone. "
06/15/2014 - "In this study, we demonstrate that Ag targeting to the CD11c(+)CD8(-) DC subpopulation in the presence of stimulating anti-CD40 Ab and TLR3 ligand polyinosinic-polycytidylic acid induces protective responses against rapidly growing tumor cells in naive animals under preventive and therapeutic treatment regimens in vivo. "
11/01/2012 - "Evidence from recent studies indicates that poly I:C can directly induce apoptosis in several types of tumor cells, thus providing a new therapeutic approach for cancer treatment. "
|3.||Neoplasm Metastasis (Metastasis)
02/01/2015 - "The results of the aforesaid experiments showed that there was a gradual increase of cellular survivability, growth, and metastasis after the cell surface stimulation of TLR-3 with Poly (I:C). "
09/15/2013 - "Using the TLR3 agonist poly(I:C), we showed as proof-of-principle that perioperative administration of a nonspecific innate immune stimulant can inhibit surgery-induced dysfunction in NK cells and attenuate metastases. "
02/01/2007 - "Surgery suppressed this MP-NKC per NK cell and promoted MADB106 metastasis, and poly I-C treatment completely abolished both effects. "
01/01/2006 - "This increase may explain the increased resistance to metastasis seen in many organs after poly I:C treatment. "
03/01/2003 - "Poly I:C elicited over 95% reduction in lung metastases and strong NK activation as assayed against YAC-1 cells in vitro. "
11/15/2010 - "Postexposure, poly(I:C) treatment of FV-infected mice resulted in a significant reduction in viral loads and protection from virus-induced leukemia. "
12/01/1985 - "In vitro treatment of undifferentiated myelomonocytic leukemia cells from the WEHI-3B cell line with 10-1,000 micrograms/ml of poly(I,C)-LC resulted in a significant increase in CSF secretion by the leukemic cells and a concomitant inhibition of their proliferation. "
05/01/1973 - "[Protective action of polyinosinic-polycytidylic acid in viral and transplanted leukemia in mice]."
11/01/2006 - "In vivo activation of NK cells, employing low doses of poly I-C or IL-12, increased in vitro NK activity against the leukemia and dramatically improved survival rates when treatment was initiated before, but not after leukemia inoculation. "
04/01/2009 - "Moreover, in addition to our previous findings that DC become activated upon phagocytosis of poly(I:C)-electroporated AML cells, these data strongly encourage future research on the potential of dsRNA-transfected AML cells and their effect to favor NK-DC cross-talk for the design of leukemia vaccines."
|5.||Melanoma (Melanoma, Malignant)
02/15/2009 - "Importantly, boosting with gp100(25-33) melanoma peptide combined with poly(I:C) 12 days after an initial priming with the same regimen significantly increased the expansion and the antitumor efficacy of adoptively transferred pmel-1 CD8(+) T cells. "
12/01/1972 - "Studies on the mechanism of the anti-melanoma effect of polyinosinic-polycytidylic acid (PIC). "
10/15/2015 - "Furthermore, knockdown of chSTING blocked polyinosinic-polycytidylic acid-, poly(deoxyadenylic-deoxythymidylic) acid-, and melanoma differentiation-associated gene 5 (MDA5)-stimulated induction of IFN-β. "
11/15/2014 - "Polyinosinic-polycytidylic acid strongly promotes the antitumor activity of NK cells via TLR3/Toll/IL-1R domain-containing adaptor molecule 1 and melanoma differentiation-associated protein-5/mitochondrial antiviral signaling protein pathways. "
04/28/2014 - "Thus, IRF3 is a key factor controlling melanoma growth through NK-cell activities, especially during poly-I:C therapy. "
|4.||Carboxymethylcellulose Sodium (Polycell)
|8.||Double-Stranded RNA (RNA, Double Stranded)
|10.||RNA (Ribonucleic Acid)